Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 412 Shares

September 11, 2026 by InsiderTrades.com

Key Points

Insider Dennis Cho sold 412 Twist Bioscience shares for approximately $50,519 at an average price of $122.62, reducing his holdings by just 0.56%. The sale was made to cover tax withholding on vested equity awards.
Twist Bioscience reported quarterly revenue of $118.38 million, up 23.2% year over year and above estimates, but its adjusted loss of $0.56 per share missed expectations.
Analyst sentiment remains mixed: the stock has a consensus “Moderate Buy” rating, while recent targets range from a bullish $144 at UBS to a bearish $45 from BWS Financial.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 412 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $122.62, for a total value of $50,519.44. Following the completion of the transaction, the insider directly owned 73,651 shares of the company's stock, valued at approximately $9,031,085.62. This trade represents a 0.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

On Wednesday, June 24th, Dennis Cho sold 14,205 shares of Twist Bioscience stock. The stock was sold at an average price of $89.75, for a total value of $1,274,898.75.
On Monday, June 22nd, Dennis Cho sold 346 shares of Twist Bioscience stock. The shares were sold at an average price of $87.32, for a total value of $30,212.72.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST opened at $126.85 on Friday. The business has a fifty day simple moving average of $112.95 and a 200 day simple moving average of $78.99. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $7.95 billion, a price-to-earnings ratio of -57.14 and a beta of 2.22. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $155.44.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. During the same period last year, the business earned $0.33 earnings per share. The firm's revenue for the quarter was up 23.2% compared to the same quarter last year. Sell-side analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on TWST shares. UBS Group assumed coverage on shares of Twist Bioscience in a research report on Wednesday. They set a "neutral" rating and a $144.00 target price on the stock. Guggenheim restated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 24th. Canaccord Genuity Group upped their price objective on Twist Bioscience from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Robert W. Baird increased their target price on Twist Bioscience from $113.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, August 4th. Finally, BWS Financial initiated coverage on Twist Bioscience in a research report on Wednesday. They set a "sell" rating and a $45.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $98.45.

Check Out Our Latest Stock Report on Twist Bioscience

Key Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

Positive Sentiment: UBS initiated coverage with a Neutral rating and a $144 price target, implying additional upside from the referenced price. While the rating is not bullish, the target provides some support for the stock’s elevated valuation. UBS initiates coverage of Twist Bioscience with neutral rating
Positive Sentiment: Twist Bioscience is scheduled to present at the Baird 2026 Global Healthcare Conference. The event could give management an opportunity to discuss demand, growth prospects and its biotechnology platform, potentially increasing investor visibility. Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
Neutral Sentiment: Insider Dennis Cho sold 412 shares for approximately $50,519, reducing his holdings by only 0.56%. Because the transaction was made to cover tax withholding related to vested equity awards, it appears less concerning than a discretionary sale.
Neutral Sentiment: The reported short-interest data shows zero shares short and a zero-day short ratio, with the stated increase listed as “NaN.” This appears to be a data-quality issue rather than evidence of a meaningful change in bearish positioning.
Neutral Sentiment: A broader article on accelerating AI and robotics adoption could support long-term interest in biotechnology automation and laboratory tools, but it does not identify a specific new catalyst for Twist Bioscience. AI and Robotics in 2026
Negative Sentiment: BWS Financial initiated coverage with a Sell rating and a $45 price target, implying substantial downside from the referenced price. This sharply bearish target highlights valuation concerns and is the strongest negative catalyst in the latest coverage.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TWST. Quarry LP acquired a new stake in shares of Twist Bioscience in the third quarter valued at approximately $28,000. Western Wealth Management LLC bought a new stake in shares of Twist Bioscience in the 1st quarter valued at about $31,000. Strs Ohio bought a new position in Twist Bioscience during the first quarter worth $33,000. Strategic Advocates LLC lifted its position in Twist Bioscience by 562.7% during the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company's stock worth $34,000 after acquiring an additional 906 shares during the last quarter. Finally, SBI Securities Co. Ltd. grew its position in shares of Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company's stock valued at $44,000 after purchasing an additional 571 shares during the last quarter.

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.